A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-90006 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Feb 2018
At a glance
- Drugs CC 90006 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 07 Feb 2018 Status changed from recruiting to completed.
- 11 Jan 2017 Status changed from not yet recruiting to recruiting.
- 21 Oct 2016 New trial record